AGIOS PHARMACEUTICALS, INC.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is a publicly-traded biopharmaceutical company founded in 2007 and headquartered in Cambridge, MA. It discovers and develops novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active R&D pipeline, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.
- 🔗 Agios Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Agios Pharmaceuticals - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Agios Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 Agios Announces Proposed Offering of Common Stock – Agios Pharmaceuticals, Inc.
- 🔗 Agios Pharmaceuticals | Flagship Pioneering
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $120M across 6 rounds prior to IPO
- Publicly traded on NASDAQ under AGIO
- Focus on cellular metabolism for cancer and rare genetic diseases
- Two approved oncology precision medicines
Ask StreetZero about AGIOS PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account